Fennec Provides Business Update and Announces Fiscal Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Fennec Pharmaceuticals (FENC) Misses Q4 EPS by 1c
March 13, 2019 6:23 AM EDTFennec Pharmaceuticals (NASDAQ: FENC) reported Q4 EPS of ($0.15), $0.01 worse than the analyst estimate of ($0.14).
Fourth Quarter and Year End 2018 Financial Results
Cash Position - Cash and cash equivalents were $22.8 million as of December 31, 2018.Research & Development (R&D) Expenses - R&D expenses were $1.7 million and $5.0 million, respectively, for the fourth quarter and year ended December 31, 2018, compared to $0.8 million and $1.9... More